合并门静脉癌栓的不可切除晚期原发性肝癌治疗进展

Treatment progress on unresectable advanced primary liver cancer with portal vein tumor thrombus

目前关于肝癌合并门静脉癌栓的最佳治疗方案仍存在争议,欧美国家倡导巴塞罗那分期唯一推荐的方式即以Sorafenib为主的靶向治疗,而亚太地区国家倡导以多种方式联合治疗为主。近年来,随着其他靶向药物、免疫治疗和放射治疗的快速发展,不同方式联合治疗已经成为一种趋势。然而尚无被广泛接受的治疗伴发癌栓的肝癌患者的标准方案。本文就肝癌合并门静脉癌栓的几种常见治疗方式及其不同联合方案进行简要阐述,以期为临床诊疗提供帮助。

At present, the optimal treatment plan for liver cancer with portal vein tumor thrombus is still controversial. The only recommended method in European and American countries according to the Barcelona staging is Sorafenib-based targeted therapy, while countries in the Asia-Pacific region advocate a combination of multiple treatments. In recent years, with the rapid development of other targeted drugs, immunotherapy and radiotherapy,combination therapy in different ways has become a trend. However, no standard has been widely accepted for the treatment of liver cancer patients with cancer thrombus. This article briefly describes several common treatment modalities of liver cancer combined with portal vein tumor thrombus and their different combinations, aiming to provide certain help for clinical diagnosis and treatment.